Discover our latest financial performance announcement and search for historical quarterly results materials.
Visit our corporate reporting archive for our Annual Reports.
2012 Fourth Quarter 06 February 2013
Simon Dingemans, CFO, and Sir Andrew Witty, CEO, discuss our fourth quarter results 2012.
- Core EPS of 112.7p and returns of £6.3bn to shareholders
- 2012 dividend of 74p (+6%)
- Group sales -1%; flat excluding disposals of OTC brands
- Successful R&D delivery: six new drugs filed since start of 2012
- Q4 2012 results announcement (PDF - 286.3KB)
- Q4 2012 results analyst presentation colour (PDF - 408.1KB)
- Q4 2012 analyst presentation bandw (PDF - 351.1KB)
- Q4 2012 analyst presentation transcript (PDF - 68.1KB)
- Q4 2012 actual growth schedules (PDF - 35.3KB)
- Q4 2012 US dollar translation (PDF - 31.8KB)